DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma

Journal of Experimental Medicine

Volumn 212, Issue 5, 2015, Pages 775-792

  Schmid, Corina A ^a   Robinson, Mark D ^b,c   Scheifinger, Nicole A ^a   Müller, Sebastian ^d,e   Cogliatti, Sergio ^f   Tzankov, Alexandar ^g   Müller, Anne ^a  

^a Institute of Molecular Cancer Research   (Switzerland)

^b Institute of Molecular Life Science IMLS   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d Institute of Food   (Switzerland)

^e ETH ZURICH   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; DNA; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 4; IBRUTINIB; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; DUSP4 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DUAL SPECIFICITY PHOSPHATASE 4 DEFICIENCY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCUS; HUMAN; HUMAN CELL; HYPOPHOSPHATASIA; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL PREDICTION; TUMOR SUPPRESSOR GENE; ANIMAL; APOPTOSIS; DEFICIENCY; FEMALE; GENETICS; MALE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MAP KINASE KINASE 4; MICE; MICE, INBRED NOD; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION;

EID: 84946401437     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20141957     Document Type: Article

References (54)

1. Agrelo, R., F. Setien, J. Espada, M.J. Artiga, M. Rodriguez, A. Pérez-Rosado, A. Sanchez-Aguilera, M.F. Fraga, M.A. Piris, and M. Esteller. 2005 Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. J. Clin. Oncol. 23:3940-3947. http://dx.doi.org/10.1200/JCO. 2005.11.650.
2. Alizadeh, A.A., M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, A. Rosenwald, J.C. Boldrick, H. Sabet, T. Tran, X. Yu, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511. http://dx.doi.org/10.1038/35000501.
3. Anders, S., D.J. McCarthy, Y. Chen, M. Okoniewski, G.K. Smyth, W. Huber, and M.D. Robinson. 2013. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat. Protoc 8:1765-1786. http://dx.doi.org/10.1038/nprot.2013.099.
4. Asmar, F., V. Punj, J. Christensen, M.T. Pedersen, A. Pedersen, A.B. Nielsen, C. Hother, U. Ralfkiaer, P. Brown, E. Ralfkiaer, et al. 2013. Genomewide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica 98:1912-1920. http://dx.doi.org/10.3324/haematol.2013.088740.
5. Balko, J.M., R.S. Cook, D.B. Vaught, M.G. Kuba, T.W. Miller, N.E. Bhola, M.E. Sanders, N.M. Granja-Ingram, J.J. Smith, I.M. Meszoely, et al. 2012 Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med 18:1052-1059. http://dx.doi.org/10.1038/nm.2795.
6. Balko, J.M., L.J. Schwarz, N.E. Bhola, R. Kurupi, P. Owens, T.W. Miller, H Gómez, R.S. Cook, and C.L. Arteaga. 2013. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basallike breast cancer. Cancer Res. 73:6346-6358. http://dx.doi.org/10.1158/ 0008-5472.CAN-13-1385.
7. Baudis, M., and M.L. Cleary. 2001. Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics. 17:1228-1229. http://dx .doi.org/10.1093/bioinformatics/17.12.1228.
8. Bethge, N., H. Honne, K. Andresen, V. Hilden, G. Trøen, K. Liestøl, H. Holte, J. Delabie, G.E. Lind, and E.B. Smeland. 2014. A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma PLoS ONE. 9:e104249. http://dx.doi.org/10.1371/journal .pone.0104249.
9. Boukhiar, M.A., C. Roger, J. Tran, R. Gressin, A. Martin, F. Ajchenbaum-Cymbalista, N. Varin-Blank, D. Ledoux, and F. Baran-Marszak. 2013 Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma. Exp. Hematol. Oncol. 2:4. http://dx.doi.org/10 .1186/2162-3619-2-4.
10. Cagnol, S., and N. Rivard. 2013. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition Oncogene. 32:564-576. http://dx.doi.org/10.1038/onc.2012.88.
11. Ceribelli, M., P.N. Kelly, A.L. Shaffer, G.W. Wright, W. Xiao, Y. Yang, L.A. Mathews Griner, R. Guha, P. Shinn, J.M. Keller, et al. 2014. Blockade of oncogenic I?B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc. Natl. Acad. Sci USA. 111:11365-11370. http://dx.doi.org/10.1073/pnas.1411701111.
12. Chambwe, N., M. Kormaksson, H. Geng, S. De, F. Michor, N.A. Johnson, R.D. Morin, D.W. Scott, L.A. Godley, R.D. Gascoyne, et al. 2014. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 123:1699-1708. http:// dx.doi.org/10.1182/blood-2013-07-509885.
13. Clozel, T., S. Yang, R.L. Elstrom, W. Tam, P. Martin, M. Kormaksson, S. Banerjee, A Vasanthakumar, B. Culjkovic, D.W. Scott, et al. 2013. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 3:1002-1019. http://dx.doi.org/10.1158/2159-8290.CD-13-0117.
14. Craig, V.J., S.B. Cogliatti, J. Imig, C. Renner, S. Neuenschwander, H. Rehrauer, R. Schlapbach, S. Dirnhofer, A. Tzankov, and A. Müller. 2011a. Mycmediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 117: 6227-6236. http://dx.doi.org/10.1182/blood-2010-10-312231.
15. Craig, V.J., S.B. Cogliatti, H. Rehrauer, T. Wündisch, and A. Müller. 2011b Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. Cancer Res 71:3616-3624. http://dx.doi.org/10.1158/0008-5472.CAN-10-3907.
16. Cultrera, J.L., and S.M. Dalia. 2012. Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Contr. 19:204-213.
17. Davis, R.E., V.N. Ngo, G. Lenz, P. Tolar, R.M. Young, P.B. Romesser, H Kohlhammer, L. Lamy, H. Zhao, Y. Yang, et al. 2010. Chronic active B-cellreceptor signalling in diffuse large B-cell lymphoma. Nature. 463:88-92 http://dx.doi.org/10.1038/nature08638.
18. De, S., R. Shaknovich, M. Riester, O. Elemento, H. Geng, M. Kormaksson, Y Jiang, B. Woolcock, N. Johnson, J.M. Polo, et al. 2013. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 9:e1003137. http://dx.doi.org/10.1371/ journal.pgen.1003137.
19. Dhanak, D., and P. Jackson. 2014. Development and classes of epigenetic drugs for cancer. Biochem. Biophys. Res. Commun. 455:58-69. http://dx.doi .org/10.1016/j.bbrc.2014.07.006.
20. 6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94:26-32. http://dx.doi.org/10.1093/jnci/94.1.26.
21. Fey, D., D.R. Croucher, W. Kolch, and B.N. Kholodenko. 2012. Crosstalk and signaling switches in mitogen-activated protein kinase cascades. Front Physiol. 3:355. http://dx.doi.org/10.3389/fphys.2012.00355.
22. Fraga, M.F., M. Berdasco, E. Ballestar, S. Ropero, P. Lopez-Nieva, L. Lopez-Serra, J.I. Martín-Subero, M.J. Calasanz, I. Lopez de Silanes, F. Setien, et al 2008. Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies. Cancer Res. 68:4116-4122. http://dx.doi.org/ 10.1158/0008-5472.CAN-08-0085.
23. Frommer, M., L.E. McDonald, D.S. Millar, C.M. Collis, F. Watt, G.W. Grigg, P.L. Molloy, and C.L. Paul. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA. 89:1827-1831. http://dx.doi.org/10 .1073/pnas.89.5.1827.
24. Guan, H., L. Xie, F. Leithäuser, L. Flossbach, P. Möller, T. Wirth, and A Ushmorov. 2010. KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood. 116:1469-1478 http://dx.doi.org/10.1182/blood-2009-12-256446.
25. Gupta, S., T. Barrett, A.J. Whitmarsh, J. Cavanagh, H.K. Sluss, B. Dérijard, and R.J. Davis. 1996. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:2760-2770.
26. Isaacson, P.G., and M.Q. Du. 2004. MALT lymphoma: from morphology to molecules Nat. Rev. Cancer. 4:644-653. http://dx.doi.org/10.1038/nrc1409
27. Jemaà, M., I. Vitale, O. Kepp, F. Berardinelli, L. Galluzzi, L. Senovilla, G. Mariño, S.A. Malik, S. Rello-Varona, D. Lissa, et al. 2012. Selective killing of p53-deficient cancer cells by SP600125. EMBO Mol. Med. 4:500-514 http://dx.doi.org/10.1002/emmm.201200228.
28. Kim, D., G. Pertea, C. Trapnell, H. Pimentel, R. Kelley, and S.L. Salzberg 2013. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14:R36. http:// dx.doi.org/10.1186/gb-2013-14-4-r36.
29. Kumaki, Y., M. Oda, and M. Okano. 2008. QUMA: quantification tool for methylation analysis. Nucleic Acids Res. 36:W170-W175. http://dx.doi.org/ 10.1093/nar/gkn294.
30. Lawrence, M., W. Huber, H. Pagès, P. Aboyoun, M. Carlson, R. Gentleman, M.T. Morgan, and V.J. Carey. 2013. Software for computing and annotating genomic ranges. PLOS Comput. Biol. 9:e1003118. http://dx.doi.org/10 .1371/journal.pcbi.1003118.
31. Lenz, G., I. Nagel, R. Siebert, A.V. Roschke, W. Sanger, G.W. Wright, S.S. Dave, B. Tan, H. Zhao, A. Rosenwald, et al. 2007. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J. Exp. Med. 204:633-643. http://dx.doi .org/10.1084/jem.20062041.
32. Lenz, G., G. Wright, S.S. Dave, W. Xiao, J. Powell, H. Zhao, W. Xu, B. Tan, N Goldschmidt, J. Iqbal, et al. Lymphoma/Leukemia Molecular Profiling Project. 2008. Stromal gene signatures in large-B-cell lymphomas. N. Engl J. Med. 359:2313-2323. http://dx.doi.org/10.1056/NEJMoa0802885.
33. Leventaki, V., E. Drakos, M. Karanikou, K. Psatha, P. Lin, E. Schlette, A Eliopoulos, T.P. Vassilakopoulos, H. Papadaki, E. Patsouris, et al. 2014. c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma. Hum. Pathol. 45:565-572 http://dx.doi.org/10.1016/j.humpath.2013.10.024.
34. KIP2 gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 100:2572-2577. http://dx.doi.org/10.1182/blood-2001-11-0026.
35. Martinez-Delgado, B., J. Fernandez-Piqueras, M.J. Garcia, E. Arranz, J. Gallego, C. Rivas, M. Robledo, and J. Benitez. 1997. Hypermethylation of a 5' CpG island of p16 is a frequent event in non-Hodgkin's lymphoma Leukemia. 11:425-428. http://dx.doi.org/10.1038/sj.leu.2400579.
36. Mathews Griner, L.A., R. Guha, P. Shinn, R.M. Young, J.M. Keller, D. Liu, I.S. Goldlust, A. Yasgar, C. McKnight, M.B. Boxer, et al. 2014. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl. Acad Sci. USA. 111:2349-2354. http://dx.doi.org/10.1073/pnas.1311846111.
37. Matsuda, K., A. Sato, M. Okada, K. Shibuya, S. Seino, K. Suzuki, E. Watanabe, Y. Narita, S. Shibui, T. Kayama, and C. Kitanaka. 2012. Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. Sci. Rep. 2:516 http://dx.doi.org/10.1038/srep00516.
38. Meyer, P.N., K. Fu, T.C. Greiner, L.M. Smith, J. Delabie, R.D. Gascoyne, G. Ott, A. Rosenwald, R.M. Braziel, E. Campo, et al. 2011. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J. Clin. Oncol. 29:200-207. http://dx.doi.org/10.1200/JCO. 2010.30.0368.
39. Muenst, S., S. Hoeller, N. Willi, S. Dirnhofera, and A. Tzankov. 2010 Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers. 29:47-53. http://dx.doi.org/10.1155/2010/404069.
40. Pasqualucci, L., and R. Dalla-Favera. 2014. SnapShot: diffuse large B cell lymphoma Cancer Cell. 25:132: e1. http://dx.doi.org/10.1016/j.ccr.2013.12.012.
41. Price, M.E., A.M. Cotton, L.L. Lam, P. Farré, E. Emberly, C.J. Brown, W.P. Robinson, and M.S. Kobor. 2013. Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenetics Chromatin. 6:4. http:// dx.doi.org/10.1186/1756-8935-6-4.
42. Robinson, C.J., C.M. Sloss, and R. Plevin. 2001. Inactivation of JNK activity by mitogen-activated protein kinase phosphatase-2 in EAhy926 endothelial cells is dependent upon agonist-specific JNK translocation to the nucleus. Cell. Signal. 13:29-41. http://dx.doi.org/10.1016/S0898-6568(00)00121-2.
43. Roschewski, M., L.M. Staudt, and W.H. Wilson. 2014. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat. Rev. Clin Oncol. 11:12-23. http://dx.doi.org/10.1038/nrclinonc.2013.197.
44. Rosenwald, A., G. Wright, K. Leroy, X. Yu, P. Gaulard, R.D. Gascoyne, W.C. Chan, T. Zhao, C. Haioun, T.C. Greiner, et al. 2003. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma J. Exp. Med. 198:851-862. http://dx.doi.org/10.1084/jem.20031074.
45. Schmitz, R., R.M. Young, M. Ceribelli, S. Jhavar, W. Xiao, M. Zhang, G Wright, A.L. Shaffer, D.J. Hodson, E. Buras, et al. 2012. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics Nature. 490:116-120. http://dx.doi.org/10.1038/nature11378.
46. Schneider, C., L. Pasqualucci, and R. Dalla-Favera. 2011. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin. Diagn. Pathol. 28:167-177. http://dx.doi.org/10.1053/j.semdp.2011.04.001.
47. Shaffer, A.L. III, R.M. Young, and L.M. Staudt. 2012. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 30:565-610. http://dx.doi .org/10.1146/annurev-immunol-020711-075027.
48. Shaknovich, R., H. Geng, N.A. Johnson, L. Tsikitas, L. Cerchietti, J.M. Greally, R.D. Gascoyne, O. Elemento, and A. Melnick. 2010. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood 116:e81-e89. http://dx.doi.org/10.1182/blood-2010-05-285320.
49. Shen, Y.H., J. Godlewski, J. Zhu, P. Sathyanarayana, V. Leaner, M.J. Birrer, A Rana, and G. Tzivion. 2003. Cross-talk between JNK/SAPK and ERK/ MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J. Biol. Chem. 278:26715-26721. http://dx.doi .org/10.1074/jbc.M303264200.
50. Teixeira, C., S.L. Stang, Y. Zheng, N.S. Beswick, and J.C. Stone. 2003. Integration of DAG signaling systems mediated by PKC-dependent phosphorylation of RasGRP3. Blood. 102:1414-1420. http://dx.doi.org/10.1182/blood-2002-11-3621.
51. Visco, C., Y. Li, Z.Y. Xu-Monette, R.N. Miranda, T.M. Green, Y. Li, A Tzankov, W. Wen, W.M. Liu, B.S. Kahl, et al. 2012. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 26: 2103-2113. http://dx.doi.org/10.1038/leu.2012.83.
52. Volk, A., J. Li, J. Xin, D. You, J. Zhang, X. Liu, Y. Xiao, P. Breslin, Z. Li, W. Wei, et al. 2014. Co-inhibition of NF-?B and JNK is synergistic in TNFexpressing human AML. J. Exp. Med. 211:1093-1108. http://dx.doi .org/10.1084/jem.20130990.
53. Waha, A., J. Felsberg, W. Hartmann, A. von Dem Knesebeck, T. Mikeska, S. Joos, M. Wolter, A. Koch, P.S. Yan, E. Endl, et al. 2010. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res. 70:1689-1699 http://dx.doi.org/10.1158/0008-5472.CAN-09-3218.
54. Wang, M., C. Atayar, S. Rosati, A. Bosga-Bouwer, P. Kluin, and L. Visser. 2009 JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J. Pathol. 218:95-103 http://dx.doi.org/10.1002/path.2521.